Mounjaro Prescribing Information: Reading It Before You Decide

The decision the prescribing information is actually helping you make

When people search for Mounjaro prescribing information, they are usually standing at a fork: should I pursue this treatment, and if so, through which route? The prescribing information (formally the Summary of Product Characteristics, or SmPC, published on the Electronic Medicines Compendium) is the authoritative document that answers the clinical half of that question. It sets out what tirzepatide is licensed for, who should not use it, how dose escalation works in principle, and what side effects have been observed. What it cannot do is tell you whether treatment is right for you specifically. That requires a prescriber who knows your history.

The SmPC confirms the licensed indication: weight management alongside a reduced-calorie diet and increased physical activity, for adults with a BMI of 30 or above, or 27 to 29.9 where at least one weight-related condition is present (type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea and osteoarthritis are among those conditions). Lower thresholds can apply for some ethnic backgrounds under UK guidance. BMI alone, though, does not settle it: a prescriber weighs contraindications, current medicines, and your broader health picture before recommending a starting dose. The tirzepatide overview on our site covers the mechanism in more depth if you want the pharmacology before your consultation.

One thing the prescribing information makes clear that surprises many people: the 2.5 mg starting dose is not the dose at which most people see meaningful weight reduction. Its job is to reduce the likelihood of early gastrointestinal discomfort while your body acclimatises. That distinction matters when you are setting expectations.

What the safety sections of the SmPC actually say

A question our prescribers hear most weeks is some version of: "I've read the side-effect list and now I'm not sure." The SmPC's adverse-event section lists every effect observed across the trial programme, regardless of how common it was. Seeing it in full can feel alarming. Context helps.

The most frequently reported effects are gastrointestinal: nausea, diarrhoea, vomiting, constipation, reflux and burping. These are most noticeable in the first days after starting or after a dose increase and, for most people, settle considerably within one to two weeks. They are also the main reason the dose escalation schedule exists, moving up slowly gives the body time to adapt. The NHS tirzepatide page presents the same information in plain language if the SmPC's clinical terminology feels dense.

The SmPC also flags conditions that require particular caution or rule out treatment altogether. A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 is a contraindication. A history of pancreatitis requires careful discussion before starting. The medicine is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive; and it is not licensed for under-18s. Certain medicines (particularly oral contraceptives) may be absorbed less reliably during the first four weeks of treatment and after each dose increase, so prescribers routinely discuss adding a non-oral contraceptive method in parallel during those windows.

If you experience severe abdominal pain that radiates to the back, seek urgent medical attention: that is the symptom pattern associated with pancreatitis, which the MHRA highlighted in a Drug Safety Update in January 2026. Side effects can also be reported directly at the MHRA's Yellow Card scheme.

NHS access, private routes, and where prescribing authority sits

Knowing the prescribing information is one thing; understanding who can actually write the prescription is another. NICE recommended tirzepatide for NHS use in December 2024 (updated September 2025), but the NHS rollout is phased by BMI and the number of qualifying conditions a person has. Many people who meet the licensed criteria do not yet meet the NHS criteria, or meet them but face long waits through specialist services. The UK prescribing guidelines page goes through those NHS thresholds in detail.

Private prescribing follows the SmPC's licensed criteria rather than the NHS's phased ones. An Independent Prescriber working outside the NHS can lawfully prescribe tirzepatide to any adult who meets the licensed eligibility and has no contraindications, following a proper clinical assessment. That assessment is not a formality: it includes identity verification, a weight check, a review of current medicines and medical history, and a discussion of expectations and risks. You can read more about whether GPs are currently prescribing Mounjaro on the NHS, and separately about the risks of trying to obtain Mounjaro without a valid prescription.

For context on how private treatment is typically priced, the Eli Lilly price increase page explains the market shift that took effect in September 2025 and why headline prices now vary as widely as they do. Pricing is relevant, but the prescribing information makes no mention of cost, it is concerned with clinical appropriateness, and that is the right order of priorities.

What reading the prescribing information should lead you to do next

The SmPC and the tirzepatide prescribing information exist for prescribers, but there is nothing stopping a patient from reading them. If anything, arriving at a consultation having read the basics tends to produce a more useful conversation. You will know the dose schedule exists, you will not be surprised by the gastrointestinal adjustment period, and you can ask specific questions rather than general ones.

What the document cannot do is tell you whether you are suitable. That is the prescriber's job. At nume, a GPhC-registered Independent Prescriber reads every consultation personally before any decision is made. If you have been on treatment elsewhere and are thinking of transferring, the Mounjaro information page covers what to bring to that conversation. If you are further back in the process and want an overview of treatment options side by side, the weight-loss treatments overview is a reasonable place to start before booking a consultation. Either way, the prescribing information has given you the framework; a prescriber fills in the specifics.